Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Summary by Weatherford Democrat
POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy…

4 Articles

Rutland HeraldRutland Herald
+2 Reposted by 2 other sources
Center

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

POTOMAC, MARYLAND / ACCESS Newswire / December 15, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) to develop innovative treatments for Alzheimer's disease, today commented on recent federal policy…

Read Full Article
stocktitan.netstocktitan.net

IGC Pharma (IGC) spotlights Alzheimer's cannabinoid trial amid Schedule III talks

IGC Pharma outlines how possible cannabis rescheduling could ease research and financing hurdles for its FDA-pathway, low-dose cannabinoid Alzheimer drug.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources lean Left
67% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Monday, December 15, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

Potomac icon

Potomac

Health & Medicine icon

Health & Medicine

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal